Quantcast

Latest Lectins Stories

2014-09-19 08:25:40

PRINCETON, N.J., Sept. 19, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (NIH) (specifically funded by the National Institute...

medical biohazard
2014-09-07 05:13:24

Chuck Bednar for redOrbit.com - Your Universe Online Containers filled with several types of potentially deadly substances, including a nearly 100-year-old vial of the toxin ricin and samples of the pathogens that cause botulism and the plague, have reportedly been discovered at US National Institutes of Health (NIH) and Food and Drug Administration (FDA) laboratories. The substances were discovered as part of a search launched in response to the accidental discovery of smallpox at an...

2014-09-02 08:29:01

All vaccinated animals exposed to a lethal aerosol of ricin toxin survive PRINCETON, N.J., Sept. 2, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin...

2014-08-28 12:29:51

NEW YORK, Aug. 27, 2014 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of investors who purchased Galectin Therapeutics Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) securities between January 6, 2014 and July 28, 2014. http://photos.prnewswire.com/prnvar/20120409/MM84375LOGO For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt....

2014-07-30 12:31:04

WAYNE, Pa., July 30, 2014 /PRNewswire/ -- Ryan & Maniskas, LLP has commenced an investigation into potential securities law violations by certain officers of Galectin Therapeutics, Inc. ("Galectin" or the "Company") (NASDAQ: GALT). http://photos.prnewswire.com/prnvar/20121112/MM11729LOGO Galectin shareholders who purchased Galectin shares should contact Richard A. Maniskas, Esquire at 877-316-3218 or at rmaniskas@rmclasslaw.com to learn more about this investigation or visit:...

2014-07-30 12:30:06

NEW YORK, July 30, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Galectin Therapeutics, Inc. ("Galectin Therapeutics" or the "Company") (NasdaqCM: GALT). Such investors are advised to contact Edward N. Gewirtz or his investor relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. The investigation focuses on whether the Company and certain of its...

2014-03-04 08:31:20

-- Successful Phase 1 Results Set the Stage for Trials in Patients with Life-Threatening Blood Disorders -- SEATTLE, March 4, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin?associated serine protease-2 (MASP-2), the...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related